Медицинская литература. Новинки

 

 

 

 

 

 

НАРУШЕНИЯ ФУНКЦИИ ЩИТОВИДНОЙ ЖЕЛЕЗЫ И СЕРДЕЧНО-СОСУДИСТАЯ СИСТЕМА

Вы можете загрузить полный текст статьи в формате pdf

Обзор посвящен влиянию тиреотоксикоза и гипотиреоза на сердечно-сосудистую систему и риск смертности от сердечно-сосудистых заболеваний. Также обсуждаются особенности заместительной терапии препаратами тиреоидных гормонов у пациентов с кардиальной патологией.

Ключевые слова:
гипотиреоз, тиреотоксикоз, левотироксин, сердечно-сосудистые заболевания.

Литература:
1. Aghini-Lombardi F., Di Bello V., Talini E. et al. Early textural and
functional alterations of left ventricular myocardium in mild hypothyroidism // Eur. J. Endocrinol. 2006. V. 155. P. 3–9.
2. Asvold B.O., Bjoro T., Nilsen T.I. et al. Association between blood
pressure and serum TSH concentration within the reference range: a population-based study // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 841–845.
3. Åsvold B.O., BjØro T., Nilsen T.I. et al. Thyrotropin Levels and
Risk of Fatal Coronary Heart Disease. The HUNT Study // Arch. Intern. Med. 2008. V. 168. P. 855–860.
4. Auer J.A., Scheibner P., Mische T. et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation // Am. Heart. J. 2001. V. 142. P. 838–842.
5. Bar-Sela S., Ehrenfeld M., Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation // Arch. Intern. Med. 1981. V. 141. P. 1191–1192.
6. Bauer D.C., Ettinger B., Browner W.S. Thyroid function and serum lipids in older women: a population-based study // Am. J. Med. 1998. V.104. P. 546–551.
7. Bibbins-Domingo K., Chertow G.M., Fried L.F. et al. Renal function
and heart failure risk in older black and white individuals: the
Health, Aging, and Body Composition Study // Arch. Intern. Med. 2006. V. 166. P. 1396–1402.
8. Bindels A.J., Westendorp R.G., Frolich M. et al. The prevalence of
subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? // Clin. Endocrinol. (Oxf.). 1999. V.50. P. 217–220.
9. Biondi B., Cooper D.S. The Clinical Significance of Subclinical Thyroid Dysfunction // Endocrin. Rev. 2008. V. 29. P. 76–131.
10. Biondi B. Cardiovascular effects of mild hypothyroidism // Thyroid. 2007. V. 17. P. 625–630.
11. Biondi B., Fazio S., Palmieri E.A. et al. Mortality in elderly patients
with subclinical hyperthyroidism // Lancet. 2002. V. 359. P. 799–800.
12. Biondi B., Klein I. Hypothyroidism as a risk factor for cardiovascular disease // Endocrin. 2004. V. 24. P. 1–13.
13. Biondi B., Palmieri E.A., Klain M. et al. Subclinical hyperthyroidism: clinical features and treatment options // Eur. J. Endocrinol. 2005. V. 152. P. 1–9.
14. Canaris G.J., Manovitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study // Arch. Intern. Med. 2000. V. 160. P. 526–534.
15. Cappola A.R. Subclinical thyroid dysfunction and the heart // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 3404–3405.
16. Cappola A.R., Fried L.P., Arnold A.M. et al. Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults // JAMA. 2006. V. 295. P. 1033–1041.
17. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis // J. Clin. Endocrinol. Met. 2003. V. 88. P. 2438–2444.
18. Clyde P.W., Harari A.E., Getka E.J. et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial // JAMA. 2003. V. 290. P. 2952–2958.
19. Cooper D.S. Approach to the patient with subclinical hyperthyroidism // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 3–9.
20. Cooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2006. V. 16. P. 109–142.
21. Croteau W., Davey J.C., Galton V.A., St Germain D.L. Cloning of
the mammalian type II iodothyronine deiodinase: a selenoprotein differentially expressed and regulated in human and rat brain and
other tissues // J. Clin. Invest. 1996. V.98. P. 405–417.
22. Escobar-Morreale H.F., Botella-Carretero J.I. Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing L-Thyroxine plus Liothyronine with L-Thyroxine Alone // Ann. Intern. Med. 2005. V. 142. P. 412–424.
23. Fazio S., Palmieri E.A., Lombardi G., Biondi B. Effects of thyroid
hormone on the cardiovascular system // Rec. Progr. Horm. Research. 2004. V. 59. P. 31–50.
24. Foldes J., Banos C., Winkler G. Subclinical hypothyroidism and
arteriosclerosis // Orv. Hetil. 2004. V. 145(31). P. 1601–1607.
25. Franklyn J.A., Maisonneuve P., Sheppard M.C. et al. Mortality after
the treatment of hyperthyroidism with radioactive iodine //
N. Engl. J. Med. 1998. V. 338. P. 712–718.
26. Gilligan D.M., Ellenbogen K.A., Epstein A.E. The management of atrial fibrillation // Am. J. Med. 1996. V. 101. P. 413–421.
27. Goldman M.B., Maloof F., Monson R.R. et al. Radioactive iodine
therapy and breast cancer. A follow-p study of hyperthyroid women // Am. J. Epidemiol. 1988. V. 127. P. 969–980.
28. Haentjens P., van Meerhaeghe A. et al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all cause mortality based on time=to-event data from cohort studies //
Eur. J. Endocrinol. 2008. V. 159(3). P. 329–341.
29. Hak A.E., Pols H.A., Visser T.J. et al. Subclinical hypothyroidism is
an independent risk factor for atherosclerosis and myocardial
infarction in elderly women: the Rotterdam Study // Ann. Intern.
Med. 2000. V. 132. P. 270–278.
30. Hall P., Lundell G., Holm L.E. Mortality in patients treated for
hyperthyroidism with iodine-131 // Acta Endocrinol.1993. V. 28.
P. 230–234.
31. Hueston W.J., Pearson W.S. Subclinical hypothyroidism and the
risk of hypercholesterolemia // Ann. Fam. Med. 2004. V. 2.
P. 351–355.
32. Iqbal A., Schirmer H., Lunde P. et al. Thyroid stimulating hormone
and left ventricular function // J. Clin. Endocrinol. Met. 2007.
V. 92. P. 3504–3510.
33. John P., Walsh J.P., Alexandra P. et al. Subclinical Thyroid
Dysfunction as a Risk Factor for Cardiovascular Disease // Arch.
Intern. Med. 2005. V. 165. P. 2467–2472.
34. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical
hypothyroidism // Thyroid. 2000. V. 10. P. 665–679.
35. Kahaly G.J., Dillmann W.H. Thyroid hormone action in the heart
// Endocrin. Rev. 2005. V. 26. P. 704–728.
36. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system // N. Engl. J. Med. 2001. V. 344. P. 501–509.
37. Klein I., Danzi S. Thyroid disease and the heart // Circulat. 2007.
V. 116. P. 1725–1735.
38. Krahn A.D., Klein G.J., Kerr C.R. et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators // Arch.
Intern. Med. 1996. V. 156. P. 2221–2224.
39. Mandel S.J., Brent G.A., Larsen P.R. Levothyroxine therapy in
patients with thyroid disease // Ann. Intern. Med. 1993. V. 119. P. 492–502.
40. Mattace-Raso F.U., van der Cammen T.J., Hofman A. et al. Arterial
stiffness and risk of coronary heart disease and stroke: the Rotterdam Study // Circulation. 2006. V. 113. P. 657–663.
41. Mercuro G., Panzuto M.G., Bina A. et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring // J. Clin. Endocrinol. Metab. 2000. V. 85.
P. 159–164.
42. Nagasaki T., Inaba M., Kumeda Y. et al. Increased pulse wave velocity in subclinical hypothyroidism // J. Clin. Endocrinol. Metab. 2006. V. 91. P. 154–158.
43. Nakazawa H.K., Sakurai K., Hamada N. et al. Management of
atrial fibrillation in the post-thyrotoxic state // Am. J. Med. 1982.
V. 72. P. 903–906.
44. Nordyke R.A, Gilbert F.I.Jr., Harada A.S. Graves’ disease.
Influence of age on clinical findings // Arch. Intern. Med. 1988.
V. 148. P. 626–631.
45. Parle J.V., Maisonneuve P., Sheppard M.C. et al. Prediction of allcause and cardiovascular mortality in elderly people from one low
serum thyrotropin result: a 10-year cohort study // Lancet. 2001.
V. 358. P. 861–865.
46. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation // Stroke. 1988. V. 19. P. 15–18.
47. Ripoli A., Pingitore A., Favilli B. et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study // J. Am. Coll. Cardiol. 2005. V. 45.
P. 439–445.
48. Roberts C.G.P., Ladenson P.W. Hypothyroidism // Lancet. 2004. V. 363. P. 793-803.
49. Rodondi N., Bauer D.C., Cappola A.R. et al. Subclinical Thyroid Dysfunction, Cardiac Function, and the Risk of Heart Failure.
The Cardiovascular Health Study // J. Am. Col. Cardiology. 2008.
V. 14. P. 11521159.
50. Rodondi N., Newman A.B., Vittinghoff E. et al. Subclinical Hypothyroidism and the Risk of Heart Failure, Other
Cardiovascular Events, and Death // Arch. Intern. Med. 2005. V. 165. P. 2460–2466.
51. Roos A.; Linn-Rasker S.P., van Domburg R.T. et al. The Starting
Dose of Levothyroxine in Primary Hypothyroidism Treatment. A Prospective, Randomized, Double-blind Trial. // Arch. Intern. Med. 2005. V. 165. P. 1714–1720.
52. Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons //
N. Engl. J. Med. 1994. V. 331. P. 1249–1252.
53. Sawka A.M., Gerstein H.C., Marriott M.J. et al. Does a combination
regimen of thyroxine (T4) and 3,5,3’-triiodothyronine improve depressive symptoms better than T4 aone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 4551–4555.
54. Sgarbi J.A., Villaca F., Garbeline B. et al. The effects of early
antithyroid therapy for endogenous subclinical hyperthyroidism on
clinical and heart abnormalities // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 1672–1677.
55. Shargorodsky M., Serov S., Gavish D. et al. Long-term thyrotropinsuppressive therapy with levothyroxine impairs small and large
artery elasticity and increases left ventricular mass in patients with thyroid carcinoma // Thyroid. 2006. V. 16. P. 381–386.
56. Siegmund W., Spieker K., Weike A.I. et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio
14 : 1) is not superior to thyroxine alone to improve well-being and
cognitive performance in hypothyroidism // Clin. Endocrinol (Oxf.). 2004. V. 60. P. 750–757.
57. Singer D.E,. Albers G.W,. Dalen J.E. et al. Antithrombotic Therapy
in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy // Chest. 2004. V. 126. P. 429S–456S.
58. Singh S., Duggal J., Molnar J. et al. Impact of subclinical thyroid
disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis // Intern. J. Cardiol. 2008. V. 125. P. 41–48.
59. Smit J.W., Eustatia-Rutten C.F., Corssmit E.P. et al. Reversible
diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebocontrolled study // J. Clin. Endocrinol. Metab. 2005. V. 90. P. 6041–6047.
60. Smith R.N., Taylor S.A., Massey J.C. Controlled clinical trial of
combined triiodothyronine and thyroxine in the treatment of hypothyroidism // Br. Med. J.1970. V. 4.P. 145–148.
61. Surks M.I., Ortiz E., Daniels G.H. et al. Subclinical thyroid disease.
Scientific review and guidelines for diagnosis and management // J. Am. Med. Assoc. 2004. V. 291. P. 228–238.
62. Tenerz A., Forberg R., Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? // J. Intern. Med. 1999. V. 228. P. 229–233.
63. Tunbridge W.M., Evered D.C., Hall R. et al. Lipid profiles and
cardiovascular disease in the Whickham area with particular reference to thyroid failure // Clin. Endocrinol. (Oxf.). 1977. V. 7. P. 495–508.
64. Vanderpump M.P., Tunbridge W.M., French J.M. et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community // Thyroid. 1996. V. 6. P. 155–160.
65. Völzke H., Schwahn C., Wallaschofski H. et al. Review: the association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 2421–2429.
66. Walsh J.P., Shiels L., Lim E.M. et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism // J. Clin.
Endocrinol. Metab. 2003. V. 88. P. 4543–4550.
67. Yazici M., Gorgulu S., Sertbas Y. et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism:
index of myocardial performance in the evaluation of left ventricular function // Intern. J. Cardiol. 2004. V. 95. P. 135–143.
68. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment // Circulat. 2002. V. 105. P. 1503–1508.
69. Zindrou D., Taylor K.M., Bagger J.P. Excess coronary artery bypass
graft mortality among women with hypothyroidism // Ann. Thorac. Surg. 2002. V. 74. P. 2121–2125.

Thyroid function disorders and cardiovascular system

The effects of hyperthyroidism and hypothyroidism on cardiovascular system and cardiovascular events mortality risk is reviewed in this article. Also the problems of levothyroxine replacement in hypothyroid patient with cardio-vascular diseases are discussed.

Keywords:
hypothyroidism, hyperthyroidism, levothyroxine, cardiovascular diseases.